Paul McGuirk is Senior Sourcing Manager for small molecule drug product at Pfizer. He has broad responsibilities that include Drug Product Manufacturing oversite, vendor management, and sourcing strategy. He has been instrumental in developing Pfizer R&D’s vendor database, which is utilized to capture relevant information required to support outsourcing activities. Paul has 10+ years of experience in various supply chain roles for both the consumer goods and pharmaceutical industries including SC Quality, Manufacturing/Packaging and Procurement. Paul holds a Bachelor of Science degree in Molecular and Cell Biology from the University of Connecticut as well as an MBA from the University of New Haven.
John Avellanet gives practical, compliance solutions to data integrity challenges for clients around the world. Winner of the 2009 & 2011 Best of Business Services award by the Small Business Commerce Association, Mr. Avellanet has earned international acclaim for his business-savvy, pragmatic FDA compliance advice. He most recently served as the industry expert reviewer for the international standard, BSI 10008 Evidential Weight and Legal Admissibility of Electronic Information (2015). He is the lead expert for the ISPE GAMP Data Integrity Working Group. He regularly trains FDA andHealth Canada officials and investigators on advanced data integrity topics.
In 2014, he co-authored the book, “Pharmaceutical Regulatory Inspections,” with several current and former regulatory agency officers, and his industry classic, “Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine (2010),” was originally featured at BIO 2011 and garnered multiple five-star reviews from industry publications, blogs, Amazon.com readers, and former FDA officials.
He has a breadth of experience designing, implementing, and being accountable for quality systems and compliance programs for FDA, DEA, ICH, GHTF/IMDRF, and ISO. For more than 15 years, John was directly accountable for regulatory compliance, records management, and information technology, most recently as a C-level executive for a Fortune 50 combination device firm. In 2006, Mr. Avellanet founded his independent lean compliance consulting and training firm, Cerulean Associates LLC.
Jim is currently the principal of Spavins Consulting and is the former SVP of Pfizer’s industry leading Pharmaceutical Sciences organization. He has experience spanning 36 years developing and bringing to patients innovative new medicines. Unique to his experience is leading global groups across all the technical disciplines of CMC development, as well as regulatory, quality, clinical supply, commercial manufacture, CI, statistics, environmental impact and economic analysis. For his leadership approach, Jim brings a strong focus beyond the necessary technical disciplines and regulations, looking at the interplay of culture, teamwork and behavior for successfully advancing programs in an effective and efficient manner. Jim has a M.A. in analytical chemistry and M.S. in chemical engineering, both from SUNY Buffalo. When not consulting, Jim is a highly-engaged grandfather.
Dr. Gautam Ranade is an active consultant to the pharmaceutical industry in the areas of Pharmaceutical R&D outsourcing, dosage form development, novel drug delivery, due diligence, CMC strategy and external alliance management. Previously, Dr. Ranade was a Senior Director, Strategic Sourcing (Pharmaceutical Sciences) in Pfizer Worldwide R&D. He has a Ph.D. in Chemical Engineering and has many years of R&D, technology transfer and supply chain experience in pharmaceutical R&D at Pfizer. In a prior role, he was a Senior Director of Drug Product Manufacturing. He made major contributions to the development and commercialization of many parenteral/oral/topical dosage forms for several Pfizer drugs. He holds 19 U.S. patents and many international patents in the areas of drug delivery and formulation development. He has 20 publications in various scientific journals in the areas of novel dosage forms and drug delivery systems. He was actively involved in outsourcing activities for drug product development. Based on his broad and extensive experience Gautam is uniquely qualified to advise on how best to navigate the complex challenges of outsourcing drug product development.
Following retirement as Vice-President in charge of External Affairs and Biosimilar Strategy for the Biotherapeutics Pharmaceutical Sciences organization of Pfizer Worldwide R&D, Dr. Bose practices business and technology strategy advising as the sole partner of AbiologicsB, LLC. At Pfizer, Arin’s group was responsible for biopharmaceutical product development outsourcing, competitive intelligence and external influencing in addition to developing and executing Pfizer’s entry strategy for biosimilars. His long biopharmaceutical industry career has included assignments in bioprocess development, clinical supply manufacturing, corporate biotechnology strategy and advocating for science-based regulations for biologics, including biosimilars. Dr. Bose’s outstanding professional accomplishments have been recognized by his election as Fellow of three leading professional organizations: American Chemical Society, American Institute of Chemical Engineers and American Institute of Medical and Biological Engineering.
Marazban Sarkari, PhD is Director of Pharmaceutical Operations with Teva’s Global Branded Products R&D group. He is a Chemical Engineer by training and has more than 15 years’ experience in outsourced pharmaceutical drug product manufacturing, and formulation and analytical development covering both large and small molecules. His teams have been involved in vendor selection, contract negotiation, project management and process scale-up and optimization. Previously he has held positions in technical operations, process and formulation development and engineering at Cephalon, Endo Pharmaceuticals and RxKinetix gaining a broad experience in the outsourcing of formulation and analytical development as well as the manufacture of clinical and commercial API and drug products. He has presented and published in the areas of new process development, vaccine formulation, novel drug delivery technologies, process optimization and monitoring.